Core Viewpoint - MediWound Ltd. is actively engaging with investors by presenting at two upcoming healthcare conferences, showcasing its advancements in enzymatic therapeutics for tissue repair [2]. Group 1: Upcoming Conferences - MediWound will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 10:40 a.m. ET, in a virtual format [2]. - The company will also participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 1:10 p.m. ET, held at the Boston Marriott Copley Place, Boston, MA [2]. - Live webcasts of both presentations will be available through the conference websites and on MediWound's Investor Relations section [2]. Group 2: Company Overview - MediWound Ltd. is a global biotechnology company specializing in enzymatic, non-surgical therapies for tissue repair [3]. - The company's FDA-approved product, NexoBrid, is designed for the removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and other international markets [3]. - MediWound's late-stage pipeline product, EscharEx, is an investigational therapy aimed at the debridement of chronic wounds, with the potential to establish a new standard of care in wound management [3].

Core Insights - MediWound Ltd. provided a corporate and financial update ahead of the J.P. Morgan Healthcare Conference, highlighting progress in its clinical pipeline and operational capabilities [1][2] Corporate Updates - The EscharEx VALUE Phase III trial for venous leg ulcers (VLUs) is ongoing, with an interim assessment and enrollment completion expected by year-end 2026 [1][6] - Plans to expand the EscharEx program to diabetic foot ulcers (DFUs) and pressure ulcers (PUs) are anticipated in 2026 [1][6] - The NexoBrid manufacturing facility has been expanded and is now fully operational, increasing production capacity sixfold [1][6] Financial Outlook - Revenue for the full year 2025 totaled $17 million [5] - Updated financial guidance projects revenues of $24–26 million for 2026, $32–35 million for 2027, and $50–55 million for 2028 [1][12] - The company reported a cash position of $54 million as of December 31, 2025, with no debt [12]